Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Improved treatment of glioblastoma: changes in survival over two decades at a single regional Centre
Umeå University, Faculty of Medicine, Department of Radiation Sciences, Oncology.
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience, Clinical Neuroscience.
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience, Clinical Neuroscience.
Umeå University, Faculty of Medicine, Department of Radiation Sciences, Oncology.
Show others and affiliations
2019 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 58, no 3, p. 334-341Article in journal (Refereed) Published
Abstract [en]

Background: Glioblastoma (GBM) is an aggressive brain tumor with a short overall survival (OS) in general. The treatment of GBM has evolved over the last decades and is today multimodal including surgical resection followed by radiochemotherapy and adjuvant chemotherapy for patients in good performance status. The aim of this study was to evaluate the development of treatment and the outcome for GBM patients at a single regional center.

Patients and methods: Survival was studied for 571 patients in our region diagnosed with GBM between 1995 and 2015. Samples from 244 patients out of those treated 2005-2015 have been included in a tissue/blood bank and a clinical database has been set up with basic patient characteristics and details on surgery and non-surgical treatment.

Results: The median OS for all patients from 1995 to 2015 was 9.3 months. There was a stepwise improvement from 6.9 to 10.3 months for patients diagnosed 1995-1996 and 2010-2015, respectively (p<.05). The 2-year survival for the same time periods improved from 7% to 18% (p<.01). After introduction of postoperative radiochemotherapy for patients in good performance status in 2005 an increased OS was noted and following implementation of intraoperative 5-aminolevulinic acid the number of tumor resection 95% did increase from 33% to 54% (p<.001). Positive prognostic factors for survival were young age, good performance status, absence of inflammatory disease, absence of diabetes or metabolic disease, tumor resection 95%, and completion of postoperative radiochemotherapy.

Discussion: The results of this study are consistent with earlier results regarding survival and prognostic factors and confirm results from randomized controlled trials in a clinical setting. Despite the improvements made, the prognosis is still dismal and the need for further research on GBM treatment is great.

Place, publisher, year, edition, pages
Taylor & Francis Group, 2019. Vol. 58, no 3, p. 334-341
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-158751DOI: 10.1080/0284186X.2019.1571278ISI: 000462947900011PubMedID: 30732527Scopus ID: 2-s2.0-85061246023OAI: oai:DiVA.org:umu-158751DiVA, id: diva2:1315927
Available from: 2019-05-15 Created: 2019-05-15 Last updated: 2026-02-17Bibliographically approved
In thesis
1. Malignant glioma − the impact of treatment, sociodemographic factors and metabolomics on survival
Open this publication in new window or tab >>Malignant glioma − the impact of treatment, sociodemographic factors and metabolomics on survival
2026 (English)Doctoral thesis, comprehensive summary (Other academic)
Alternative title[sv]
Överlevnad vid malignt gliom − betydelsen av behandling, sociodemografiska faktorer och metabolomik
Abstract [en]

Background: Gliomas constitute a large group of brain tumors. Glioblastoma, isocitrate dehydrogenase (IDH)-wildtype is the most common and most aggressive type of glioma. The initial treatment often includes surgery and postoperative radiotherapy and/or chemotherapy. Despite extensive treatment, the overall survival for patients with glioblastoma, IDH-wildtype is short, around 10 months in an unselected patient cohort. The prognosis is affected by several factors related to the patient (for example age, world health organization (WHO) performance status (PS) and comorbidities), the tumor (molecular biology/mutations) and the given treatment.

Aims: The aim of this thesis was to investigate prognostic and predictive clinical, sociodemographic and metabolic factors in glioma, especially glioblastoma, IDH-wildtype. 

Methods: Survival was studied for all adult patients with glioma, WHO grade 4 in northern Sweden from 1995–2015. Tumor tissues from 244 patients undergoing surgery for glioblastoma, IDH-wildtype or astrocytoma, IDH-mutant, grade 4 from 2005–2015 were collected and stored in a biobank. Clinical data on prognostic factors and treatment were collected and analyzed for the patients with a tumor tissue sample in the biobank (the biobank cohort). Metabolite analyses were performed on tumor tissue samples through mass spectrometry-based methods and the metabolite data were evaluated in relation to overall survival and time to next intervention.Survival in relation to sociodemographic factors was studied for patients with glioma, WHO grade 1–4 using the RISK North database. In RISK North, the National Quality Registry for Central Nervous System Tumors and sociodemographic registries were linked to study socioeconomic status, cohabitation status, travel time to the regional hospital and region of residence. Socioeconomic status was estimated through educational level.

Results: In Study I, an increased survival from 6.9–10.3 months was observed over time for all glioblastoma patients in northern Sweden diagnosed between 1995–2015. Clinical prognostic factors were studied in the biobank cohort. In the multivariable analysis, longer survival was associated with younger age at diagnosis, good WHO PS, extensive surgery, type of postoperative treatment and absence of metabolic disease/diabetes and inflammatory disease.In Study II, an association was found between higher educational level and longer survival for patients with glioma, WHO grade 3–4. No differences in prognosis were observed when analyzing cohabitation status, travel time to the regional hospital or region of residence for glioma, WHO grade 1–4.In Study III, different metabolites were associated with survival and time to next intervention. For survival, the analysis highlighted mainly metabolites related to amino acid, carbohydrate, and fatty acid metabolism, and for time to next intervention, amino acids and amino acid metabolites. Three predictive metabolic markers were found in the group treated with resective surgery and radiochemotherapy: indolelactate, 5,6-dihydrouracil and uridine 5’-diphospho-N-acetylglucosamine. Prognostic and predictive metabolites were merged into scores that were associated with survival or time to next intervention in multivariable analyses adjusted for other prognostic factors.

Conclusion: This thesis enhances the knowledge of the factors associated with survival and treatment response in glioma. The progress in treatment is studied in a clinical setting where earlier known prognostic factors are validated, and new data is presented on sociodemographic factors and on metabolic markers. Glioblastoma is a disease with, in many cases a short, expected survival and there is a substantial need for continued research with the main goal to improve the treatment for the patients.

Place, publisher, year, edition, pages
Umeå: Umeå University, 2026. p. 69
Series
Umeå University medical dissertations, ISSN 0346-6612 ; 2404
Keywords
Glioma, prognosis, treatment, sociodemographic factors, metabolic markers
National Category
Cancer and Oncology
Research subject
Oncology; Medical Biochemistry; Neurosurgery
Identifiers
urn:nbn:se:umu:diva-249994 (URN)978-91-8070-916-3 (ISBN)978-91-8070-917-0 (ISBN)
Public defence
2026-03-20, Hörsalen, Östersunds sjukhus, Östersund, 13:00 (Swedish)
Opponent
Supervisors
Available from: 2026-02-20 Created: 2026-02-17 Last updated: 2026-02-17Bibliographically approved

Open Access in DiVA

fulltext(1379 kB)417 downloads
File information
File name FULLTEXT01.pdfFile size 1379 kBChecksum SHA-512
24bdeb38d84c08b0e381c97c18af9548891feb17d46cbc57c4238da6acfe5ac72e1dcd32857576cd99483a20dbe9159e4634eaf0178efd997e75239034a558b1
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Johansson, MikaelBergenheim, A. TommySandström, Maria

Search in DiVA

By author/editor
Eriksson, MariaJohansson, MikaelBergenheim, A. TommySandström, Maria
By organisation
OncologyClinical Neuroscience
In the same journal
Acta Oncologica
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 418 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 1151 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf